
Windtree Therapeutics EBITDA | WINT
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Windtree Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -26.1 M | -20.5 M | -40.8 M | -77.1 M | -32.3 M | -26.5 M | -19.4 M | -16.5 M | -37.8 M | -50.9 M | -42.4 M | -43.8 M | -36.7 M | -23.3 M | -24 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -16.5 M | -77.1 M | -34.5 M |
Quarterly EBITDA Windtree Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -19.5 M | -3.95 M | -4.07 M | - | - | - | -4.38 M | - | - | - | -4.17 M | - | -4.14 M | -17 M | -7.87 M | - | -8.01 M | -45.3 M | -9.03 M | - | -8.58 M | -7.86 M | -6.66 M | -4.55 M | -7.01 M | -6.36 M | -6.61 M | -4.85 M | -3.35 M | -2.95 M | -4.8 M | -3.5 M | -4.79 M | -6.04 M | -8.06 M | -6.37 M | -7.53 M | -9.85 M | -13.9 M | -9.78 M | -7.82 M | -9.88 M | -10.7 M | -11.2 M | -9.75 M | -10.6 M | -10.6 M | -10.3 M | -10.3 M | -10.4 M | -12.4 M | -12.4 M | -9.14 M | -8.24 M | -6.29 M | -5.9 M | -5.22 M | -5.74 M | -5.74 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.95 M | -45.3 M | -8.67 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
-30.6 M | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
-6.32 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
-104 M | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
-22.8 M | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
-137 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-29.2 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
-270 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
-135 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
-214 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
-11.1 M | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
351 M | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-417 K | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
-3.08 M | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
83 K | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
228 K | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
-41.1 M | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
-36.6 M | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
-62.7 M | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
-76.6 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
-60.8 M | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
-1.05 B | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
-186 M | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
-27.7 M | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
-154 M | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
-4.32 M | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
5.25 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-219 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
-14.4 M | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
-18.7 M | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
-12.1 M | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
-14 M | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
-46.2 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
-36.8 M | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
37.3 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
-210 M | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
-22.7 M | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
-32.8 M | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
-64.5 M | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
-42.4 M | - | - | $ 728 M |